GRFS Key Stats
- Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Ag... 7:00 AM
- Stocks Mostly Higher In Late Trade; Actavis Jumps May 10
- Stocks Mixed In Early Afternoon; Priceline, Nvidia Up May 10
- Europe Emerges As Leader Of Foreign Stocks' Q1 Earnings May 9
- Stocks Stay On Track, Log More Gains May 7
- Stocks Rise With Dow, S&P Headed For New Record Highs May 7
- 4 Stocks Pushing The Drugs Industry Downward May 7
- Stocks Mixed As Nasdaq Wobbles: EOG Resources Bolts Higher May 7
- Stocks Mixed In Afternoon; Qihoo, Alaska Air Jump May 6
- Acquisitions, Global Thinking Boost Spanish Biotech Grifols May 2
GRFS Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Grifols is up 60.24% over the last year vs S&P 500 Total Return up 31.97%, Cadence Pharmaceuticals up 139.0%, and ARCA biopharma down 5.73%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for GRFS
Pro Report PDF for GRFS
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download GRFS Pro Report PDF
Pro Strategies Featuring GRFS
Did Grifols make it into our Pro Portfolio Strategies?